Aldeyra Therapeutics Soars on Clinical Trial Results

On September 12, Aldeyra Therapeutics reported positive results from its clinical trial of a treatment for dry eye disease. The company plans to continue its phase 2 clinical trials in early 2018.

The news triggered a Sonal level 2 alert at 7:00 am before the stock price rose from $4.

The stock price surged over 50% to $6.75 within the first few hours of trading before fading back to $5.66 through the course the day. Over the next two trading sessions, Aldeyra continued its upward trend. The closing price on was $10.25 on September 14.

 

With just one signal, investors had three great trading opportunities over the next three days.

 

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!